Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria
Daniel G Wootton, Hyginus Opara, Giancarlo A Biagini, Maxwell K Kanjala, Stephan Duparc, Paula L Kirby, Mary Woessner, Colin Neate, Maggie Nyirenda, Hannah Blencowe, Queen Dube-Mbeye, Thomas Kanyok, Stephen Ward, Malcolm Molyneux, Sam Dunyo, Peter A Winstanley, Daniel G Wootton, Hyginus Opara, Giancarlo A Biagini, Maxwell K Kanjala, Stephan Duparc, Paula L Kirby, Mary Woessner, Colin Neate, Maggie Nyirenda, Hannah Blencowe, Queen Dube-Mbeye, Thomas Kanyok, Stephen Ward, Malcolm Molyneux, Sam Dunyo, Peter A Winstanley
Abstract
The objective of this study was to determine the appropriate dose of artesunate for use in a fixed dose combination therapy with chlorproguanil-dapsone (CPG-DDS) for the treatment of uncomplicated falciparum malaria.
Methods: Open-label clinical trial comparing CPG-DDS alone or with artesunate 4, 2, or 1 mg/kg at medical centers in Blantyre, Malawi and Farafenni, The Gambia. The trial was conducted between June 2002 and February 2005, including 116 adults (median age 27 years) and 107 children (median age 38 months) with acute uncomplicated Plasmodium falciparum malaria. Subjects were randomized into 4 groups to receive CPG-DDS alone or plus 4, 2 or 1 mg/kg of artesunate once daily for 3 days. Assessments took place on Days 0-3 in hospital and follow-up on Days 7 and 14 as out-patients. Efficacy was evaluated in the Day 3 per-protocol (PP) population using mean time to reduce baseline parasitemia by 90% (PC90). A number of secondary outcomes were also included. Appropriate artesunate dose was determined using a pre-defined decision matrix based on primary and secondary outcomes. Treatment emergent adverse events were recorded from clinical assessments and blood parameters. Safety was evaluated in the intent to treat (ITT) population.
Results: In the Day 3 PP population for the adult group (N = 85), mean time to PC90 was 19.1 h in the CPG-DDS group, significantly longer than for the +artesunate 1 mg/kg (12.5 h; treatment difference -6.6 h [95%CI -11.8, -1.5]), 2 mg/kg (10.7 h; -8.4 h [95%CI -13.6, -3.2]) and 4 mg/kg (10.3 h; -8.7 h [95%CI -14.1, -3.2]) groups. For children in the Day 3 PP population (N = 92), mean time to PC90 was 21.1 h in the CPG-DDS group, similar to the +artesunate 1 mg/kg group (17.7 h; -3.3 h [95%CI -8.6, 2.0]), though the +artesunate 2 mg/kg and 4 mg/kg groups had significantly shorter mean times to PC90 versus CPG-DDS; 14.4 h (treatment difference -6.4 h [95%CI -11.7, -1.0]) and 12.8 h (-7.4 h [95%CI -12.9, -1.8]), respectively. An analysis of mean time to PC90 for the Day 14 PP and ITT populations was consistent with the primary analysis. Treatment emergent, drug-related adverse events were experienced in 35.3% (41/116) of adults and 70.1% (75/107) of children; mostly hematological and gastroenterological. The nature and incidence of adverse events was similar between the groups. No dose-related changes in laboratory parameters were observed. Nine serious adverse events due to any cause occurred in five subjects including two cases of hemolysis believed to be associated with drug treatment (one adult, one child). One adult died of anaphylactic shock, not associated with investigational therapy.
Conclusions: CPG-DDS plus artesunate demonstrated advantages over CPG-DDS alone for the primary efficacy endpoint (mean time to PC90) except in children for the 1 mg/kg artesunate dose. Based on a pre-defined decision matrix, the primary endpoint in the child group supported an artesunate dose of 4 mg/kg. Secondary endpoints also supported a 4 mg/kg artesunate dose to take forward into the remainder of the development program.
Trial registration: ClinicalTrials.gov NCT00519467.
Conflict of interest statement
Competing Interests: Paula Kirby and Mary Woessner are current employees of GlaxoSmithKline, and Stephan Duparc and Colin Neate are former employees of GlaxoSmithKline.
Figures
![Figure 1. Trial profile of the study…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2258152/bin/pone.0001779.g001.jpg)
![Figure 2. Primary efficacy outcome: mean time…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2258152/bin/pone.0001779.g002.jpg)
![Figure 3. Results for Day 3 per-protocol…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2258152/bin/pone.0001779.g003.jpg)
![Figure 4. Adults: Percentage of patients who…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2258152/bin/pone.0001779.g004.jpg)
![Figure 5. Children: Percentage of patients who…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2258152/bin/pone.0001779.g005.jpg)
References
- World Health Organisation. 2005. World Malaria Report. Geneva: World Health Organisation. Available online at: (Last accessed 23rd December, 2006)
- Hyde JE. Drug-resistant malaria. Trends Parasitol. 2005;21:494–498.
- World Health Organisation. Geneva: World Health Organisation; 2004. Position Paper of WHO Roll Back Malaria Department on malaria treatment.
- Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, et al. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg. 1997;91:574–577.
- van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94:545–548.
- Alin MH, Bjorkman A. Concentration and time dependency of artemisinin efficacy against Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1994;50:771–776.
- Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother. 2002;46:778–782.
- Dutta GP, Bajpai R, Vishwakarma RA. Artemisinin (qinghaosu)–a new gametocytocidal drug for malaria. Chemotherapy. 1989;35:200–207.
- Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2005;2:e330.
- Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193:1151–1159.
- Hallett RL, Sutherland CJ, Alexander N, Ord R, Jawara M, et al. Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother. 2004;48:3940–3943.
- Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996;347:1654–1658.
- Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg. 1999;60:547–555.
- Winstanley P. Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health. 2001;6:952–954.
- Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 2004;363:1843–1848.
- Nzila AM, Nduati E, Mberu EK, Hopkins Sibley C, Monks SA, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis. 2000;181:2023–2028.
- Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, et al. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet. 2002;360:1136–1143.
- World Health Organisation. 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organisation. Available online at: (Last accessed 6th January, 2007)
- Murphy S, Watkins WM, Bray PG, Lowe B, Winstanley PA, et al. Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine. Am J Trop Med Hyg. 1995;53:303–305.
- World Health Organisation. 2002. Monitoring antimalarial drug resistance: report of a WHO consultation. Geneva: World Health Organisation. Available online at: (Last accessed December 28th, 2006)
- Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg. 2003;68:133–139.
- Joint United Nations Programme on HIV/AIDS. Geneva: UNAIDS; May, 2006. Report on the global AIDS epidemic 2006. Available online at: (Last accessed December 23rd, 2006)
- Laufer MK, van Oosterhout JJ, Thesing PC, Thumba F, Zijlstra EE, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis. 2006;193:872–878.
- Borrmann S, Adegnika AA, Missinou MA, Binder RK, Issifou S, et al. Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob Agents Chemother. 2003;47:901–904.
- Schwarz NG, Oyakhirome S, Potschke M, Glaser B, Klouwenberg PK, et al. 5-day nonobserved artesunate monotherapy for treating uncomplicated falciparum malaria in young Gabonese children. Am J Trop Med Hyg. 2005;73:705–709.
- Degowin RL, Eppes RB, Powell RD, Carson PE. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ. 1966;35:165–179.
- World Health Organisation. Geneva: World Health Organisation; 2004. Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated falciparum malaria in Africa: report of a technical consultation convened by WHO. Available online at: (Last accessed 23rd December, 2006)
Source: PubMed